Sanofi wins big in battle for nano-drug maker

January 29, 2018
Sanofi announced a second major acquisition this month that will boost its work in treating blood disorders.

France's Sanofi announced Monday that it had reached a deal to acquire Belgian biotech firm Ablynx that values the firm at 3.9 billion euros ($4.8 billion), beating out Danish rival Novo Nordisk for the nano-drug maker.

Novo Nordisk earlier this month made a 2.6-billion-euro offer to buy the firm that is developing nano-drugs to treat blood disorders, which Ablynx rejected as too little.

Chief executive Olivier Brandicourt said by acquiring Ablynx that Sanofi will be expanding its portfolio of drugs that are close to market and "strengthening our platform for growth in rare blood disorders."

Ablynx specialises in the development of nanobodies: small fragments of antibodies that like larger antibodies can bind onto the antigens that cause an .

One of its nanobodies furthest along in development, caplacizumab, aims to treat a certain type of blood clot.

Ablynx's Edwin Moses said "we believe Sanofi's global infrastructure, commitment to innovation and commercial capabilities will accelerate our ability to deliver our pipeline" of products under development to the market.

Sanofi said that while it expected the addition of Ablynx would increase the long-term value of the company to shareholders by adding to its pipeline of drugs under development, research expenses would mean no increased earnings per share this year or in 2019.

The purchase of Ablynx is the second major acquisition by Sanofi this month, after announcing last week it would buy US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion (9.4 billion euros).

Sanofi's shares dipped 0.2 percent in a Paris market up slightly overall.

Explore further: Novo Nordisk woos Belgian nano-drug maker

Related Stories

Novo Nordisk woos Belgian nano-drug maker

January 8, 2018
Denmark's Novo Nordisk, the world's leading insulin manufacturer, announced Monday an offer to buy the Belgian biotech firm Ablynx for 2.6 billion euros ($3.1 billion).

Sanofi buys US haemophilia treatment firm for $11.6 bn (Update)

January 22, 2018
French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion.

Belgium's Ablynx in Merck cancer research tie-up: firm

February 3, 2014
Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

Sanofi profits hit by falling US sales of diabetes drugs

November 2, 2017
French pharmaceutical giant Sanofi on Thursday posted a drop in third-quarter earnings, hit by a decline in sales of its diabetes drugs in the United States.

French pharma giant Sanofi says profits up in 2016

February 8, 2017
French pharmaceuticals giant Sanofi said Wednesday that cost-cutting measures and the strong performance of its rare diseases business drove up profits last year.

French drug giant Sanofi vows hostile bid for US prey (Update)

April 29, 2016
French pharmaceutical giant Sanofi vowed to open a hostile takeover battle Friday after its $9.3 billion (8.2 million-euro) offer for US cancer drug maker Medivation was dismissed for being too cheap.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.